Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Value Will Pave The Way For Innovative Brands, Pfizer’s Germano Says

Executive Summary

Global Innovative Pharma Business President Geno Germano sat down with “The Pink Sheet” to discuss growth strategy, M&A and Pfizer’s increasing focus on value in a changing health care world.

You may also be interested in...

Pfizer Gets Palbociclib To NDA Finish Line On Phase II Data

Pfizer finished a rolling NDA for the high-profile breast cancer drug, the first-in-class CDK-4/6 inhibitor. Whether or not FDA will agree Phase II data results from the PALOMA-1 trial are sufficient to grant accelerated approval remains to be seen.

Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe

Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.

J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update

Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts